Quantcast

Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) – Global Industry Analysis, Size, Share, Trends and Forecast, 2012 – 2018

January 9, 2014

DUBLIN, January 9, 2014 /PRNewswire/ –

Dublin – Research and Markets (
http://www.researchandmarkets.com/research/pkv9nd/liver_diseases) has announced the
addition of the “Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines,
Targeted Therapy And Immunosuppressants) – Global Industry Analysis, Size, Share, Trends
And Forecast, 2012 – 2018″
[http://www.researchandmarkets.com/research/pkv9nd/liver_diseases ] report to their
offering.

(Logo:
http://photos.prnewswire.com/prnh/20130307/600769 )

This report covers the performance of the various drugs class segment used in liver
disease therapeutics in terms of their revenue. The global market for liver diseases
therapeutics is classified into seven drug class segments namely, anti-viral drugs,
vaccines, immunosuppressants, immunoglobulins, targeted therapy, corticosteroids and
chemotherapy with their estimated and forecasted market size from 2012 to 2018, along with
their compound annual growth rate.

This report also covers an in-depth competitive analysis for the market, taking into
consideration some of the major market players. The market players considered are: Abbott
Laboratories, Astellas Pharma Inc, Gilead Science Inc., Merck & Co., Bristol-Myers Squibb,
Novartis, Pfizer and Roche. A detailed analysis of their business strategies, company
overview, financial overview, product portfolio and recent developments is also provided
in the report.

We have used secondary research for deriving our market numbers for each segment of
the research report and further validated our analysis with C-level executives of major
companies operating in liver diseases therapeutics market through the means of primary
research to finally come up with our results. This research is specially designed to
estimate and analyze the performance of liver diseases therapeutics in a global scenario.
This research provides in-depth analysis of liver diseases therapeutics market sales,
trend analysis by segments.

Key Topics Covered:

        1 Preface
        1.1 Report Description
        1.2 Research Methodology

        2 Executive Summary

        3 Market Overview
        3.1 Introduction
        3.2 Market Size
        3.3 Comparative Analysis Of Global Liver Diseases Therapeutics Market, By Drug Class,
         2011 & 2018
        3.4 Liver Diseases Therapeutics Market Dynamics
        3.5 Porter's Five Forces Analysis For Liver Diseases Therapeutics Market

        4 Liver Diseases Classification And Therapy Options
        4.1 Alcohol Induced Liver Disease
        4.2 Autoimmune Liver Disorder
        4.3 Hepatocellular Carcinoma
        4.4 Non-Alcoholic Fatty Liver Disease
        4.5 Viral/Hepatitis Liver Disorder

        5 Liver Diseases Therapeutics Market, By Drug Class
        5.1 Immunosuppressants
        5.2 Chemotherapy Drugs
        5.3 Targeted Therapy Drugs
        5.4 Vaccines
        5.5 Anti-Viral Drugs
        5.6 Immunoglobulins
        5.7 Corticosteriods

        6 Competitive Landscape

        7 Recommendations
        7.1 Market Strategy For Success
        7.2 Barriers To Be Considered

        8 Company Profiles

Companies Mentioned:

        - Abbott Laboratories
        - Astellas Pharma Inc.
        - Bristol-Myers Squibb
        - Gilead Sciences
        - Glaxosmithkline Plc
        - F. Hoffmann-La Roche Ltdmerck & Co. Inc
        - Novartis Ag
        - Sanofi S.A
        - Pfizer Inc.
        - Takeda Pharmaceutical
        - Valeant Pharmaceuticals
        - Watson Pharmaceuticals, Inc.

For more information visit

http://www.researchandmarkets.com/research/pkv9nd/liver_diseases

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


    Photo: 

http://photos.prnewswire.com/prnh/20130307/600769

SOURCE Research and Markets


Source: PR Newswire



comments powered by Disqus